Everything below concerns growth hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-27. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Kardashev mentions another hypothesis that, in his opinion, is capable of explaining the dynamics of the supercivilizations: the "feedback effect" (theorized by Sebastian von Hoerner in 1975), which is based on the hypothesis that at a high technological level, civilizations tend to converge rather than to isolate themselves. The distance between supercivilizations could then be determined by half the time of the technological evolution of the oldest civilization, which would be about 3 to 4 billion years. On the other hand, this supercivilization may not have been present in our galaxy for a long time. Kardashev concludes by saying that since the expansion of the Universe is infinite, the number and lifetime of such supercivilizations are also infinite.
=== Subtypes of bone sarcoma === Osteosarcoma Chondrosarcoma Poorly differentiated round/spindle cell tumors (includes Ewing sarcoma) Hemangioendothelioma Angiosarcoma Fibrosarcoma/myofibrosarcoma Chordoma Adamantinoma Other: Liposarcoma Leiomyosarcoma Malignant peripheral nerve sheath tumor Rhabdomyosarcoma Synovial sarcoma Malignant solitary fibrous tumor.
At the time, the multiple neutron absorption was thought to be an extremely rare process, but the identification of 244Pu indicated that still more neutrons could have been captured by the uranium, producing new elements heavier than californium.
Many of his reports, which he wrote primarily for the newspaper Frankfurter Allgemeine Zeitung, the news magazine Der Spiegel and the weekly newspaper Die Zeit, were also published in expanded versions as books, becoming bestsellers. In cooperation with the Avicenna relief organization founded by his father Djavad Kermani, Kermani initiated fundraising campaigns for aid projects in Aceh (Indonesia), Lesbos, Madagascar and Tigray after returning from his reporting trips. Kermani's books have been translated into numerous languages. In his public statements and speeches, Kermani regularly comments on issues of society, politics and religion. Jan-Werner Müller described him in the New York Review of Books as one of Germany's most thought-provoking intellectual voices. From 2009 to 2012, Kermani was a senior fellow at the Kulturwissenschaftliches Institut (KWI) Institute for Advanced Humanities Study in Essen. In 2009, he was appointed a corresponding member of the Akademie der Wissenschaften [Academy of Sciences] in Hamburg. In the summer semester of 2010, Kermani served as guest lecturer in poetics at the Goethe University Frankfurt, where he gave the Frankfurter Poetikvorlesungen [Frankfurt Poetics Lectures], which were later published as a book entitled Über den Zufall. Jean Paul, Hölderlin und der Roman, den ich schreibe [On Contingency: Jean Paul, Hölderlin, and the Novel I Am Writing]. In the winter semester of 2011/12, Kermani delivered the Göttingen Poetics Lecture series, and in 2014, the Mainz Poetics Lecture series.
Sources: en.wikipedia.org
=== Hub status === Air-cargo company Federal Express moved its base to Memphis from Little Rock, Arkansas, in 1973. Memphis was selected because of its temperate climate and location in the middle of the country. The decision was credited with enabling the city to go from a river port of decreasing economic relevance to an important global distribution center. Shipments flew into and out of the hub overnight on aircraft that exclusively carried cargo. To accommodate the company's rapid growth and larger aircraft, a "superhub" facility opened in 1981, featuring new methods of handling freight containers and high-speed conveyor belts operated by a computer system. Memphis became the busiest airport by cargo traffic worldwide in 1992. By 2000, the hub processed over one million packages per night, and FedEx ran 150 daily flights from Memphis. Southern Airways developed a busy operation in Memphis. In 1979, the carrier merged with North Central Airlines to form Republic Airlines, which expanded the Memphis operation into a hub in 1985. Republic began the first international flight from Memphis to Puerto Vallarta in December 1985. As of 1986, it connected the airport to 60 destinations. That year the company merged into Northwest Airlines, which maintained the hub. Northwest lost money in Memphis and nearly closed the hub in 1993. The airline then worked on its local reputation and on-time record, and passenger counts began to rise. KLM, a partner of Northwest, launched the airport's first transatlantic passenger flight to Amsterdam in June 1995.
=== Natural cancers === Some cancer studies with non-rodent animals have been performed with the unmodified Sendai virus. Thus, after intratumoral injections of the virus, complete or partial remission of mast cell tumors (mastocytomas) was observed in dogs affected by this disease. Short-term remission after an intravenous injection of SeV was described in a patient with acute leukemia treated in the Clinical Research Center of University Hospitals of Cleveland (US) by multiple viruses in 1964. It is also reported that the Moscow strain of SeV was tested by V. Senin and his team as an anticancer agent in a few dozen patients affected by various malignancies with metastatic growth in Russia in the 1990s. The virus was injected intradermally or intratumorally and it caused fever in less than half of the treated patients, which usually disappeared within 24 hours. Occasionally, the virus administration caused inflammation of the primary tumor and metastases. Clinical outcomes were variable. A small proportion of treated patients experienced pronounced long-term remission with the disappearance of primary tumors and metastases. Sometimes the remission lasted 5–10 years or more after virotherapy. Brief descriptions of the medical records of the patients that experiences long-term remission are presented in the patent. Intratumoral injection of UV irradiated and inactivated SeV resulted in an antitumor effect in a few melanoma patients with stage IIIC or IV progressive disease with skin or lymph metastasis.
== Discovery and development == Tralokinumab was discovered by Cambridge Antibody Technology scientists using protein optimization based on Ribosome Display. They used the extensive data sets from ribosome display to patent protect CAT-354 in a world-first of sequence-activity-relationship claims. In 2004, clinical development of CAT-354 was initiated with this first study completing in 2005. On 21 July 2011, MedImmune LLC initiated a Phase IIb, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma. In 2016, MedImmune and AstraZeneca started developing tralokinumab for asthma (Phase III) and atopic dermatitis (Phase IIb) while clinical development for moderate-to-severe ulcerative colitis and idiopathic pulmonary fibrosis (IPF) have been discontinued. In July of that year AstraZeneca licensed tralokinumab to Leo Pharma for skin diseases. A phase IIb study of tralokinumab found that treatment was associated with early and sustained improvements in atopic dermatitis symptoms and tralokinumab had an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with atopic dermatitis. In June 2017, Leo Pharma started phase III clinical trials with tralokinumab in atopic dermatitis.
=== Oath of neutrality === On 15 March 1900, Lord Roberts proclaimed an amnesty for all burghers, except leaders, who took an oath of neutrality and returned quietly to their homes. It is estimated that between 12,000 and 14,000 burghers took this oath between March and June 1900.
During this period, Taiwan was a major investor in Malaysia, ranking among its top five sources of foreign investment, even reaching the top spot in 1990 and 1994. Mahathir himself visited Taiwan in 1984, 1988, and 1997, with two of these visits involving transit diplomacy at Taoyuan Airport. In 1988, he led a delegation of three cabinet ministers on a discreet visit to Taiwan, which drew criticism from Beijing. However, Mahathir defended the trip by emphasizing that Malaysia's engagement with Taiwan was based solely on economic considerations rather than political recognition. His government also facilitated closer ties by allowing Taiwan's trade office in Malaysia to be upgraded and by engaging in high-level exchanges, such as meetings with Taiwanese leaders like Premier Lien Chan in 1993.
Sources: en.wikipedia.org
== Early life == Geneviève Meurgues was born on 4 February 1931 in Paris, into a family originally from Saint-Germain-de-Modéon. She had sister and brother, Christiane and Bernard. Until 1962, she worked in a medical analysis laboratory while completing her education in chemistry and biochemistry at the Conservatoire national des arts et métiers. She graduated as a chemical engineer in 1967, writing her thesis on the nucleic acids of the fungus Aspergillus niger.
A radionuclide (radioactive nuclide, radioisotope, radioactive isotope, or unstable isotope) is a nuclide that is unstable and known to undergo radioactive decay into a different nuclide, which may be another radionuclide (see decay chain) or be stable. Radioactive decay is a random process at the level of single atoms: it is impossible to predict when one particular atom will decay. For a collection of atoms of a single nuclide, their average decay rate can be measured, and its half-life (t1/2) calculated. Half-lives vary by 55 orders of magnitude and have no known limits. All chemical elements have radionuclides - even the lightest, hydrogen, has a well-known radionuclide, tritium (though helium, lithium, and boron have none with half-life over a second). Elements heavier than lead (Z > 82), and the elements technetium and promethium, have only radionuclides and do not exist in stable forms, though bismuth can be treated as stable with the half-life of its natural isotope being over a trillion times longer than the current age of the universe. Radiation emitted by radionuclides is almost always ionizing radiation and exposure above a certain level can cause damage to living organisms.
===== Meglitinide ===== Meglitinides are similar to sulfonylureas, as they bind to beta cells in the pancreas, but differ by the site of binding to the intended receptor and the drugs' affinities to the receptor. As a result, they have a shorter duration of action compared to sulfonylureas and require higher blood glucose levels to begin to secrete insulin. Both meglitinides, known as nateglinide and repanglinide, are sold in formulations combined with metformin. A repaglinide/metformin combination is sold as Prandimet, or as its generic equivalent.
Sichuan Corps Four mobile detachments Tibet Corps Three mobile detachments Tianjin Corps Yunnan Corps Three mobile detachments Xinjiang Corps Seven mobile detachments XPCC Corps (Not to be confused with the XPCC itself) Zhejiang Corps
Jung's acquaintance with alchemy came between 1928 and 1930 when he was introduced to a manuscript of The Secret of the Golden Flower, translated by Richard Wilhelm. The work and writings of Jung from the 1930s onwards shifted to a focus on the psychological significance of alchemy. In 1944, Jung published Psychology and Alchemy, in which he analyzed the alchemical symbols and came to the conclusion that there is a direct relationship between them and the psychoanalytical process. He argued that the alchemical process was the transformation of the impure soul (lead) to perfected soul (gold), and a metaphor for the individuation process. In 1963, Mysterium Coniunctionis first appeared in English as part of The Collected Works of C. G. Jung. Mysterium Coniunctionis was Jung's last major book and focused on the "Mysterium Coniunctionis" archetype, known as the sacred marriage between the sun and moon. Jung argued that the stages of the alchemists, the blackening, the whitening, the reddening, and the yellowing, could be taken as symbolic of individuation—his chosen term for personal growth (75).
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。